Aytu BioPharma Q4 FY26 net loss narrows to USD 15,000; revenue rises 6.4% to USD 16.1 million vs Q4 FY25

By Public Technologies
  • Aytu Biopharma reported Q4 fiscal 2026 net revenue rose 6.4% to USD 16.1 million versus the year-ago quarter.
  • Net loss narrowed to USD 15,000, versus USD 19.82 million a year earlier.
  • Full-year net revenue fell 13.3% to USD 57.6 million, and net loss widened to USD 14.25 million.
  • EXXUA produced USD 3.94 million of Q4 net revenue, its first full quarter of launch, and USD 6.57 million for the year.
  • CEO Josh Disbrow said Q4 prescriptions topped 3,300, more than doubled sequentially, while June reached a record 1,261 scripts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609221605ACCESSWRNAPR_____1223174) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.